Insulin Lispro Mix 25 + Humalog® Mix 25
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 16/100
16
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clamp Study
Conditions
Clamp Study
Trial Timeline
Apr 12, 2017 → Jul 13, 2017
NCT ID
NCT03606018About Insulin Lispro Mix 25 + Humalog® Mix 25
Insulin Lispro Mix 25 + Humalog® Mix 25 is a pre-clinical stage product being developed by GEROPHARM for Clamp Study. The current trial status is completed. This product is registered under clinical trial identifier NCT03606018. Target conditions include Clamp Study.
What happened to similar drugs?
0 of 2 similar drugs in Clamp Study were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
3
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03606018 | Pre-clinical | Completed |
Competing Products
9 competing products in Clamp Study
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Insulin Aspart + NovoRapid® Penfill® | GEROPHARM | Pre-clinical | 16 |
| RinGlar® + Lantus® | GEROPHARM | Pre-clinical | 16 |
| GP-40081 + NovoMix® 30 Penfill® | GEROPHARM | Pre-clinical | 16 |
| Insulin Lispro + Humalog® | GEROPHARM | Pre-clinical | 16 |
| Antithrombin gamma + physiological saline | Kyowa Kirin | Phase 3 | 40 |
| Placebo + RLX030 | Novartis | Phase 2 | 27 |
| recombinant human relaxin | Novartis | Phase 1 | 33 |
| Sildenafil citrate | Pfizer | Phase 2 | 27 |
| Furosemide | Pacific Biosciences | Phase 3 | 30 |